In this study, we examined the antidiabetic effect and probable mechanisms of Rhodiola sachalinensis root extract (RS). The extract was examined by thin-layer chromatographic analysis, and the main compound was determined to be a polysaccharide. In streptozotocininduced diabetic rats, RS showed significant hypoglycemic activity by lowering blood glucose (at doses of 200 and 400 mg/kg for 40 days). The levels of serum total cholesterol and triglycerides in RS-treated diabetic rats were lower than in control diabetic rats. A significant increase in the serum insulin levels of diabetic rats following RS treatment was also observed. Furthermore, RS treatment decreased malondialdehyde levels, while increasing superoxide dismutase, catalase and glutathione peroxidase activities of the liver and kidney of diabetic rats. At the same time, RS did not show any significant toxicity in LD(50) and single-cell gel electrophoresis assays. These results indicate that RS has hypoglycemic and hypolipidemic activities and is an effective scavenger of free radicals that inhibits lipid peroxidation. The antioxidant and pancreatic beta-cell-protective activities of RS may be the main mechanisms of the observed antidiabetic effect of RS.
"The key antioxidant enzymes which include superoxide dismutase ( " SOD " ), glutathione peroxidase ( " GPx " ), and catalase ( " CAT " ) form the backbone of the enzymatic antioxidant cascade and offer protection to cells and tissues against oxidative injury . In this context, nuclear factor erythroid 2-related factor 2 ( " Nrf 2 " ) has been recognized as one of the key transcriptional factors that can play a significant protective role by controlling the antioxidant response element-(ARE-) dependent gene regulation in response to oxidative stress   . "
[Show abstract][Hide abstract] ABSTRACT: Based on the preliminary screening of eight indigenous putative probiotic Lactobacilli, Lactobacillus fermentum Lf1 was selected for assessing its antioxidative efficacy in DSS colitis mouse model based on its ability to enhance the expression of "Nrf2" by 6.43-fold and malondialdehyde (MDA) inhibition by 78.1 ± 0.24% in HT-29 cells under H2O2 stress. The Disease Activity Index and histological scores of Lf1-treated mice were lower than the control group. However, expression of "Nrf2" was not observed in Lf1-treated mice. A significant increase in the expression of antioxidative enzymes such as SOD2 and TrxR-1 was recorded in both of the groups. The expression of SOD2 was significantly downregulated in colitis-induced mice by -100.00-fold relative to control group, and the downregulation was considerably reduced to -37.04-fold in colitis Lf1 treatment group. Almost, a similar trend was recorded in case of "thioredoxin" expression, though "CAT" was refractile to expression. The Lf1-treated group had decreased malondialdehyde level as compared to colitis control (37.92 ± 6.31 versus 91.13 ± 5.76 μM/g). These results point towards Lf1-induced activation of the antioxidant enzyme system in the mouse model and its prospects to be explored as a new strategy for IBD management.
BioMed Research International 07/2014; 2014(3):206732. DOI:10.1155/2014/206732 · 2.71 Impact Factor
"Rhodiola rosea has long been used as a medicinal plant and has been reported to have various pharmacological properties, including antifatigue and antistress activity , anticancer, antioxidant and immune enhancing and stimulating sexual activity , anti-inflammation , improvement of glucose and lipid metabolism [6, 7], antiarrhythmic effect , and enhancement of angiogenesis . However, the effects of Rhodiola rosea on atherosclerotic lesions formation are still unclear. "
[Show abstract][Hide abstract] ABSTRACT: Salidroside is isolated from Rhodiola rosea and is one of the main active components in Rhodiola species. The present study was designed to evaluate the effects of Salidroside on atherosclerotic plaque formation in high-fat diet-(HFD-) fed female LDL receptor knockout (LDLr(-/-)) mice. LDLr(-/-) mice fed an atherogenic HFD for 12 weeks were divided into two groups. One group was administered Salidroside (50 mg/kg/oral gavage) daily for 8 weeks, while the control group was administered saline. Salidroside treatment reduced serum lipids levels and the plaque area through the arch to the abdominal aorta. Furthermore, Salidroside improved macrophage content and enhanced collagen and smooth muscle cells contents in the aortic sinus. These changes were associated with reduced MCP-1, VCAM-1, and VCAM-1 protein expression in atherosclerotic aortas. All these results suggest that Salidroside decreases atherosclerotic plaques formation via effects on lipid lowering and anti-inflammation in HFD-fed LDLr(-/-) mice.
Evidence-based Complementary and Alternative Medicine 10/2012; 2012(5):607508. DOI:10.1155/2012/607508 · 1.88 Impact Factor
[Show abstract][Hide abstract] ABSTRACT: It has been confirmed that diabetes mellitus (DM) carries increased oxidative stress. This study evaluated the effects of salidroside from Rhodiolae Radix on diabetes-induced oxidative stress in mice. After induction of diabetes, diabetic mice were administered daily doses of 50, 100 and 200 mg/kg salidroside for 28 days. Body weights, fasting blood glucose (FBG), serum insulin, TC (total cholesterol), TG (triglyceride), malondialdehyde (MDA), superoxide dismutase (SOD), glutathione peroxidase (GPx) and catalase (CAT) were measured. Results showed that salidroside possessed hypoglycemic activity and protective effects against diabetes-induced oxidative stress, which could significantly reduce FBG, TC, TG and MDA levels, and at same time increase serum insulin levels, SOD, GPx and CAT activities. Therefore, salidroside should be considered as a candidate for future studies on diabetes.
Li Li, Lin Feng, Wei-Dan Jiang, Jun Jiang, Pei Wu, Juan Zhao, Sheng-Yao Kuang, Ling Tang, Wu-Neng Tang, Yong-An Zhang, Xiao-Qiu Zhou, Yang Liu
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.